Forodesine: review of preclinical and clinical data.

Abstract

Purine nucleoside phosphorylase (PNP) is an important catalytic enzyme in the purine salvage pathway; its deficiency is associated with T-cell lymphopenia and with humoral deficiency. This clinical observation led to the investigation of PNP inhibitors and their possible clinical application in the management of hematologic malignancies, notably those of T-cell lineage. Forodesine is the most potent of the PNP inhibitors. Its effect appears to be linked to increased 2 -deoxyguanosine levels in plasma, which in turn is converted to 2 -deoxyguanosine triphosphate in target cells and disrupts DNA synthesis. Several preclinical studies have shown forodesine's effect against lymphocytes in vitro and in vivo, and these findings have led to several Phase I/II studies in patients with lymphoid neoplasms. Early clinical trials show that forodesine has promise as a single agent for the treatment of relapsed/refractory hematologic malignancies, and combination therapies might be warranted to improve clinical results.

• Authors: Aref Al-Kali, Varsha Gandhi, Mohamad Ayoubi, Michael Keating, Farhad Ravandi
• Journal: Future oncology (London, England) (Future Oncol) Vol. 6 Issue 8 Pg. 1211-7 (Aug 2010) ISSN: 1744-8301 [Electronic] England
• PMID: 20799866 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)

Chemical References

• Purine Nucleosides
• Pyrimidinones
• forodesine
• Purine-Nucleoside Phosphorylase

Topics

• Animals
• Clinical Trials as Topic
• Drug Evaluation, Preclinical
• Humans
• Neoplasms (drug therapy, enzymology, immunology)
• Purine Nucleosides (therapeutic use)
• Purine-Nucleoside Phosphorylase (antagonists & inhibitors)
• Pyrimidinones (therapeutic use)
• T-Lymphocytes (immunology)